Different gastoroesophageal reflux symptoms of middle-aged to elderly asthma and chronic obstructive pulmonary disease (COPD) patients by Shimizu, Yasuo et al.
Original Article
 J. Clin. Biochem. Nutr. | March 2012 | vol. 50 | no. 2 | 169–175 doi: 10.3164/jcbn.11 75
©2012 JCBN
)JCBN Journal of Clinical Biochemistry and Nutrition 0912-0009 1880-5086 the Society for Free Radical Research Japan Kyoto, Japan jcbn11-75 10.3164/jcbn.11-75 Original Article Different gastoroesophageal reflux symptoms 
of middle aged to elderly asthma and chronic 
obstructive pulmonary disease (COPD) patients
Yasuo Shimizu,1,2,3,* Kunio Dobashi,4 Motoyasu Kusano1 and Masatomo Mori1
1Department of Medicine and Molecular Science, Gunma University Graduate School of Medicine, 3 39 15 Showa machi, Maebashi, Gunma 371 8511, Japan
2Jobu Hospital for Respiratory Disease, 586 1 Taguchi machi, Maebashi, Gunma 371 0048, Japan
3Department of Pulmonary Medicine, Maebashi Red Cross Hospital, 3 21 36 Asahi cho Maebashi, Gunma 371 0014, Japan
4Gunma University School of Health Sciences, 3 39 15 Showa machi, Maebashi, Gunma 371 8511, Japan
*To whom correspondence should be addressed.    
E mail: yasuos@med.gunma u.ac.jp
?? (Received 24 May, 2011; Accepted 6 July, 2011; Published online 11 November, 2011)
Copyright © 200? JCBN 200? This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unre- stricted use, distribution, and reproduction in any medium, pro- vided the original work is properly cited. Symptomatic differences and the impact of gastroesophageal
reflux disease (GERD) have not been clarified in patients with
asthma and chronic obstructive pulmonary disease (COPD). The
purpose of this study is to assess the differences of GERD symp 
toms among asthma, COPD, and disease control patients, and
determine the impact of GERD symptoms on exacerbation of
asthma or COPD by using a new questionnaire for GERD. A total
of 120 subjects underwent assessment with the frequency scale
for the symptoms of GERD (FSSG) questionnaire, including 40 age 
matched patients in each of the asthma, COPD, and disease control
groups. Asthma and control patients had more regurgitation 
related symptoms than COPD patients (p<0.05), while COPD
patients had more dysmotility related symptoms than asthma
patients (p<0.01) or disease control patients (p<0.01). The most
distinctive symptom of asthma patients with GERD was an
unusual sensation in the throat, while bloated stomach was the
chief symptom of COPD patients with GERD, and these symptoms
were associated with disease exacerbations. The presence of
GERD diagnosed by the total score of FSSG influences the exacer 
bation of COPD. GERD symptoms differed between asthma and
COPD patients, and the presence of GERD diagnosed by the FSSG
influences the exacerbation of COPD.
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Introduction Gastroesophageal reflux (GER) is a potential trigger for supra-
esophageal manifestations of asthma and chronic obstructive
pulmonary disease (COPD).(1,2) The prevalance of gastroesophageal
reflux disease (GERD) in asthma patients was 42% to 69%
according to the questionnaire for the diagnosis of reflux disease
(QUEST).(3,4) In COPD patients, the prevalance was 37% according
to the Mayo clinic GERD questionnaire.(5,6) GER is common in
patients with pulmonary disease and is involved in the patho-
physiology of exacerbation of asthma and COPD, but proton
pump inhibitors (PPIs) show limited efficacy for improvement of
pulmonary function and respiratory symptoms in asthma or COPD
patients with GERD.(7–9) Failure of PPI therapy is observed in
patients who are diagnosed as having GERD by endoscopy, pH
testing and esophageal impedance.(10) Therefore, another mecha-
nism that has attracted attention is gastric motor activity.(11) In
contrast, QUEST covers more typical symptoms of acid regurgita-
tion, the frequency scale for the symptoms of GERD (FSSG) is
a recently developed questionnaire that covers 12 symptoms,
including not only typical regurgitation symptoms such as “heart-
burn” but also dysmotility symptoms such as “heavy stomach”.(12)
GERD also changes with age,(13) and there have been no reports
about the prevalance and features of GERD symptoms in age-
matched asthma and COPD patients with GERD diagnosed by the
FSSG.
The aims of this study were to compare the prevalence of
GERD and the symptoms of GERD among asthma, COPD, and
disease control patients. The impact of GERD (evaluated by the
FSSG) on exacerbation of asthma and COPD was also examined.
Subjects and Methods
Subjects. A total of 120 subjects underwent the FSSG,
including 40 patients with asthma, 40 patients with COPD, and 40
disease control subjects without asthma or COPD. The character-
istics of the subjects enrolled in this study are shown in Table 1.
The diagnosis of asthma was established according to the Global
Initiative for Asthma report (GINA),(14) as described previously,(4)
while a diagnosis of COPD was established according to the
Global Initiative for Chronic obstructive Lung disease report
(GOLD).(15) The disease control patients had hypertension (n =2 6 ) ,
hyperlipidemia (n = 11), insomnia (n = 1), prostatomegaly (n =1 ) ,
and cervical spondylosis (n = 1) without respiratory symptoms
and without receiving respiratory medications. Patients were
excluded if they had a history of esophageal, gastric, or duodenal
surgery, were using acid-suppressing drugs of PPI, H2 receptor
antagonist or gastroprokinetic agents such as selective serotonin
(5HT4) agonists, were mentally incompetent, or were being
treated with an angiotensin-converting enzyme (ACE) inhibitor.
Since COPD occurs rather older than young, less than 50 years
old were excluded.
Protocol. This study is retrospective cohort-study. Pulmonary
function tests [% vital capacity (% VC), forced vital capacity
(FVC), and forced expiratory volume in 1 sec (FEV1.0)] were
measured with a CHESTAC −55V (CHEST MI, Tokyo, Japan)
at Gunma University and with a CHESTAC −5500 or −8800
(CHEST MI, Tokyo, Japan) at Jobu Hospital. Pulmonary function
in disease control was not measured because this study is
retrospective study and measuring pulmonary function was not
approved by institute committee. Sputum was obtained after
inhaling 3 ml of 3% saline via a nebulizer, and cells were counted.
If a patient could not expectorate the sputum, 3 ml of 6% saline
were nebulized repeatedly. Defimition of adequate sputum was
one in which there were fewer than 20% squamous cells and
where viability was <50%.(16) The eosinophil count was deter-
mined by Hansel stain.(17) For calculation of the dose of inhaled




budesonide.(18) Exacerbation of asthma and COPD was defined as
worsening that required an unscheduled visit to the local doctor,
emergency department, or hospital, or else needed treatment with
oral or intravenous corticosteroids at least one episode during the
past two years.(6,19) The FSSG has been proven to be a useful
questionnaire for the assessment of GERD, and it was used to
determine the prevalence and symptoms of GERD.(12) This
questionnaire is composed of 12 questions (Table 2), which are
scored to indicate the frequency of symptoms as follows: never =
0, occasionally = 1, sometimes = 2, often = 3, and always = 4. The
cut-off score for diagnosis of GERD was defined as 8 points. The
unique feature of the FSSG is that the questions cover both acid
regurgitation-related symptoms (questions 1, 4, 6, 7, 9, 10, and 12)
and gastric dysmotility-related symptoms (questions 2, 3, 5, 8, and
11). This study was conducted according to the Declaration of
Helsinki, and all patients gave informed consent before enroll-
ment. The Human Research Committee of Gunma University and
the Human Research Committee of Jobu Hospital for Respiratory
Disease both approved this study.
Statistics. Data are expressed as the mean (SD). Comparison
of parameters between two groups was done by Student’s t test.
Comparisons among three groups were done by one-way ANOVA
with Bonferroni’s multiple comparison test. Differences in
frequency between regurgitation and dysmotility symptoms were
assessed by the chi-square test. A p value of less than 0.05 was
considered significant. Comparison of exacerbation number of
patients between GERD positive and negative were performed
by Fisher’s exact test.
Results
The characteristics of each group are shown in Table 1. Age did
not differ among the asthma, COPD, and disease control patients.
The body mass index (BMI) of the COPD group was lower than
that of the other two groups (p<0.05). Regular treatments given for
asthma patients were oral corticosteroids, inhaled steroids/long-
acting  β2 agonists, oral theophyllines, leukotrines and inhaled
steroids. Regular treatments given for COPD patients were
Table 1. Characteristics of asthma, COPD, and disease control
*Statistically significance between asthma patients and COPD patients. #Statistically significance between COPD patients
and disease control patients.
Asthma COPD Disease control
Age, year 65.5 ± 9.4 69.8 ± 10.2 65.0 ± 9.9
Sex (male/female) 19/21 38/2 22/18
Body mass index, kg/m2 23.1 ± 3.8 20.3 ± 2.6*,# 23.8 ± 4.0
Smoking, pack years 7.1 ± 19.5 27.1 ± 17.0*,# 5.4 ± 8.3
Smoking, cur , ex , never  5, 5, 30 17, 22, 1 8, 5, 27
Eosinophil of peripheral blood, % 3.8 ± 2.1 1.6 ± 0.3*
Sputum, %
neutrophil 55.2 ± 30.7 84.4 ± 12.1*
eosiniphil 34.7 ± 32.8 8.3 ± 6.0*
basophil 0.58 ± 1.3 0.7 ± 1.6
macrophage 9.6 ± 11.1 6.7 ± 7.3
Pulmonary function
%VC, % 99.7 ± 22.0 88.7 ± 25.2
FVC, L 2.9 ± 1.0 2.6 ± 1.1
FEV 1.0, L 1.7 ± 0.8 1.4 ± 0.9
FEV1.0/FVC % pred 78.5 ± 27.0 62.2 ± 22.9
FEV1.0/FVC, % 65.9 ± 21.2 50.2 ± 13.9
Medication
Oral corticosteroids 20 2
Oral theophyllines 13 15
Oral expectrants 2 8
Oral anti histamines 2 0
Leukotrienes 13 0
Tulobuterol patches 9 11
Inhaled steroids 13 6
Inhaled β2 agonists 4 4
Inhaled steroids/β2 agonists 17 12
Inhaled anticholinergics 1 16
Table 2. Questions of FSSG*
*FSSG: The frequency of scale for the symptoms of GERD.
Questions
q1 Do you get heartburn?
q2 Does your stomach get bloated?
q3 Does your stomach ever feel heavy after meals?
q4 Do you sometimes subconsciously rub your chest with your hand?
q5 Do you ever feel sick after meals?
q6 Do you get heartburn after meals?
q7 Do you have an unusual (e.g. burning) sensation in your throart?
q8 Do you feel full while eating meals?
q9 Do some things get stuck when you swallow?
q10 Do you get bitter liquid (acid) coming up into your throat?
q11 Do you burp a lot?
q12 Do you get heartburn if you bend over? J. Clin. Biochem. Nutr. | March 2012 | vol. 50 | no. 2 | 171
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inhaled anticholinergics, oral theophilines, inhaled steroids/long
acting β2 agonists, inhaled steroids and β2 agonist patches. The
prevalence of GERD (detected by the FSSG) was not significantly
different among the three groups of asthma patients (10/40, 25%),
COPD patients (13/40, 32.5%) and disease control patients (11/40,
27.5%), as shown in Table 3. Among patients with GERD, the
COPD patients were older than the asthma and disease control
patients (p<0.05). BMI was not statistically different among the
groups with GERD. Of the 13 GERD-positive COPD patients,
some of the patients received inhaled steroid only or inhaled
steroid and long acting β2 agonists patches without inhaled
anticholinergics because of having glaucoma or dry mouth due to
adverse event of anticholinergics.
The unique feature of the FSSG is that the questions are divided
into those covering acid regurgitation-related symptoms (questions
1, 4, 6, 7, 9, 10, and 12) and those for gastric dysmotility-related
symptoms (questions 2, 3, 5, 8, and 11). When regurgitation- and
dysmotility-related symptoms were compared among each group,
the number of patients showing predominance of regurgitation-
related symptoms was higher in the asthma group (p<0.005) and
the disease control group (p<0.01) than in the COPD group
(Fig. 1). The number of patients showing predominance of
dysmotility-related symptoms was higher in the COPD group than
in the asthma group (p<0.005) and the disease control group
(p<0.01). Among GERD-positive patients, the number of patients
showing predominance of regurgitation-related symptoms was
higher in the asthma group (p<0.01) and the disease control group
Table 3. Characteristics of asthma, COPD, and disease control having GERD
*Statistically significance between asthma patients and COPD patients. #Statistically significance between COPD patients
and disease control patients.
Asthma COPD Disease control
Frequency of GERD, %, GERD pt/total pt 25.0, 10/40 32.5, 13/40 27.5, 11/40
Age, year 64.2 ± 9.8 72.2 ± 7.5* 64.3 ± 7.5
Sex (male/female) 2/8 13/0* 4/7
Body mass index, kg/m2 22.8 ± 4.4 20.7 ± 3.6 22.7 ± 2.6
Smoking, pack years 10.0 ± 31.6 28.9 ± 16.5* 4.1 ± 8.3#
Smoking, cur , ex , never  0, 0, 10 4, 9, 0 2, 2, 8
Eosinophil of peripheral blood, % 3.4 ± 1.1 0.3 ± 1.1*
Sputum, %
neutrophils 59.1 ± 32.4 92.5 ± 5.8*
eosiniphils 33.1 ± 34.5 6.4 ± 5.5*
metachromatic cells (basophils) 0.29 ± 0.76 0
macrophages 7.1 ± 7.4 1.1 ± 0.85*
Pulmonary functions
%VC, % 93.2 ± 18.5 67.0 ± 17.1*
FVC, L 2.1 ± 0.40 1.9 ± 0.66
FEV 1.0, L 1.5 ± 0.4 0.93 ± 0.3*
FEV 1.0% pred, % 81.9 ± 28.1 52.9 ± 16.1
FEV 1.0/FVC, % 72.2 ± 22.3 50.8 ± 10.1
Regular use of medication
Oral corticosteroids 2 0
Oral theophyllines 6 5
Oral expectrants 2 2
Oral anti histamines 1 0
Leukotrienes 4 0
β2 agonist patches 8 3
Inhaled steroids 2 6
Inhaled β2 agonists 0 0
Inhaled steroids/β2 agonists 6 1
Inhaled anticholinergics 0 8
Fig. 1. Chief symptoms of asthma patients (n = 40), COPD patients
(n = 40), and disease control patients (n = 40). The total score for acid
regurgitation related symptoms (questions 1, 4, 6, 7, 9, 10, and 12) and
the total score for dysmotility related symptoms (questions 2, 3, 5, 8,
and 11) were compared. The number of patients in each group with a
higher score for acid regurgitation symptoms (A>M), the same score for
both symptoms (A = M), or a higher score for dysmotility symptoms
(A<M) was determined. *Significant difference between asthma and
COPD. #Significant difference between COPD and disease controls.doi: 10.3164/jcbn.11 75
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(p<0.01) than in the COPD group, while the number with pre-
dominance of dysmotility-related symptoms was higher in the
COPD group than in the asthma group (p<0.01) or the disease
control group (p<0.01), as shown in Fig. 2. Presence GERD
evaluated by FSSG was the risk of COPD exacerbation (OR = 4.8,
95% CI 1.25–18.5, p<0.05), however not in asthma (OR = 3.0,
95% CI 0.69–13.1) (Table 4).
When the scores for each question of patients with GERD
were compared among the groups, the mean scores for question 7
(unusual sensation in the throat) was significantly higher in
asthma patients and disease control patients with GERD (p<0.01)
than in COPD patients with GERD. The mean score for question 2
(bloated stomach) was significantly higher in COPD patients
than in disease control patients (p<0.05), but was not significantly
different from asthma patients (Figs. 3 a–c). Each data expressed
by mean (SD) was shown in Table 5. The score for question 2 was
higher in COPD patients with GERD having a history of exacerba-
tion of COPD during the past 2 years than in COPD patients with
GERD without having a history of exacerbation (p<0.01)
(Fig. 4a). Also, the score for question 7 was higher in asthma
patients with GERD having a history of exacerbation during the
past 2 years than in asthma patients with GERD without having a
history of exacerbation (p<0.01) (Fig. 4b).
Discussion
A previous survey using the FSSG revealed that the prevalence
of GER was 27.4% among asthma patients,(20) and that its pre-
valence was higher among COPD patients (26.8%) than among
age-matched healthy controls (12.5%).(21) The prevalence of
GERD detected in the present study was similar to that in other
studies using the FSSG, but the prevalence of GERD in the control
group was higher in the present study (32.5% vs 27.5%) compared
with a previous study.(21) A previous FSSG survey of metabolic
syndrome patients, revealed that hypertension or hyperlipidemia
were independent risk factors for GERD and metabolic syndrome
patients showed high score of FSSG.(22) A possible reason for the
different prevalences in the control groups was different back-
ground factors, i.e., healthy versus diseased subjects including
those with hypertension and hyperlipidemia, and also this was the
one of the reason that no statistical difference in prevalance among
asthma, COPD and control groups in present study.
Fig. 2. Chief symptoms in asthma patients (n = 10), COPD patients
(n = 13) and disease control patients (n = 11) who were diagnosed as
having GERD by the FSSG survey in each group. The total score for acid
regurgitation related symptoms (questions 1, 4, 6, 7, 9, 10, and 12) and
the total score for dysmotility related symptoms (questions 2, 3, 5, 8,
and 11) were compared. The number of patients in each group with a
higher score for acid regurgitation symptoms (A>M), the same score for
both symptoms (A = M), or a higher score for dysmotility symptoms
(A<M) was examined. *Significant difference between asthma and
COPD. #Significant difference between COPD and disease controls.
Table 4. Associations between exacerbations and presence of GERD symptoms in asthma and COPD patients
The number of patients having a histrory of disease exacerbations (+) or not having a history of exacerbation (−) were compared in presence of
GERD (+) symptoms or without presence of GERD (−) symptoms. *Statistically significance between GERD (+) and GERD (−) patients in COPD. Data
are presented as odds ratios (ORs) and % 95% confidence interval (CI).
Exacerbation (+) Exacerbation (−) p value OR 95% CI
Asthma GERD (+) 6 4
Asthma GERD (−) 10 20 0.16 3 0.69–13.1
COPD GERD (+) 8 5
COPD GERD (−) 9 27 0.038* 4.8 1.25–18.5
Fig. 3. Mean score for each FFSG question in asthma (a), COPD (b), and disease control (c) patients with GERD. Asthma patients (n = 10), COPD
patients (n = 13), and disease control patients were diagnosed as having GERD by the FSSG survey in each group. Vertical bars from 0 to 2 show the
mean score for each question. *Significant difference between asthma and COPD. #Significant difference between COPD and disease controls. J. Clin. Biochem. Nutr. | March 2012 | vol. 50 | no. 2 | 173
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Dysmotility-related symptoms were prominent in the COPD
patients. A survey using the Rome II criteria for irritable bowel
syndrome showed that 14% of COPD patients fulfilled these
criteria.(23) A physiological study using manometry showed a 35%
decrease of peristalsis in COPD patients.(24) To our knowledge,
there has only been this study about esophageal motility, and there
have been no studies of intestinal peristalsis in COPD patients. A
decrease of lower esophageal sphincter pressure is related to the
mechanism of GER in both asthma and COPD patients,(25–27) while
dysmotility from the esophagus to intestines seemed to contribute
to GER symptoms in COPD. Dysmotility symptoms are frequently
induced by rather functional dyspepsia (FD) than GERD. Rome III
consensus for diagnosis of FD needs the absence of organic
disorder, such as esophagitis, gastric atrophy or erosive gastro-
duodnal leisions on endoscopy.(28) Present study was questionnaire
based survey, and did not include the endoscopic examination.
Therefore it was difficult to discriminate between GERD and
FD patients. The FSSG contains questions about dysmotility
symptoms, in addition to acid-reflux-related symptoms, allowing
it to detect GERD symptoms widely. However, the FSSG was
inferior to QUEST for the diagnosis of reflux esophagitis in
distinguishing between GERD and other condition, such as FD,
gastric ulcer (GU) and duodenal ulcer (DU).(29) Further analysis
is needed to proportion of FD in COPD patients.
In asthma patients, the typical symptom detected by the FSSG
was an unusual sensation in the throat. Bloated stomach also
showed a high score, but it was not statistically different from the
other items. There is an increase of tonsillitis, pharyngitis, and
laryngitis among respiratory tract diseases in patients with GERD,
and GERD is also considered to play a role in 55% of hoarse-
ness.(2,30) Possible mechanisms leading to an unusual sensation in
the throat are direct acid reflux or acidic gas reflux.(31) Another
mechanism is stimulation of esophageal or laryngeal sensory
nerves by gastric acid, because some sensory nerves from these
sites terminate in the same region of the central nervous system.(32)
The limitation of this result is that factors of patients in this study
might affect the unusual sensation in throat. Medications such as
β2 agonists and oral theophilines might aggravate GERD, and use
of inhaled steroids might have been a cause of “unusual sensation
in throat”.(33) Eosinophil ratio was actually high in asthma patients,
and several patients received oral corticosteroids which indicated
those patients were severe asthma, and this might affect on
unusual sensation in the throat in asthma patients.
In COPD patients, the typical symptom detected by the FSSG
was bloated stomach. As mentioned above, dysmotility of the
esophagus has been speculated to have an association with
COPD,(23) but there has not been enough investigation. It is
known that the severity of atrophic gastritis increases with a longer
duration of COPD, as well as with the severity of hypoxia and
bronchial obstruction.(34) Ventilation affects both gastric mucosal
blood flow and gastric mucosal pH.(35) Thus, COPD can influence
the mucosa and blood flow of the stomach, and changes of the
mucosal integrity or blood flow may have an effect on GER.
Recently published longitudinal study showed that a history of
gastroesophageal reflux or heartburn is associated with frequent-
exacerbation phenotype in COPD patients.(36) Patients who had
GER symptoms of reflux or heartburn had significantly more
hospitalizations related to their COPD.(6) In present study, COPD
patients had more dysmotility symptoms than reflux or heartburn
symtoms, and presence of GERD evaluated by total score of FSSG
was the risk of COPD exacerbations. Therefore, dysmotility to
esophagus to intestine possibly affects COPD exacerbation. In
asthma patients, presence of GERD evaluated by total score of
FSSG did not affect the asthma exacerbations. Asthma patients
Table 5. Scores for questions of FSSG on patients with GERD
FSSG was composed by 12 questions (q1 to q12), and each score was indicated mean (SD) in asthma with GERD (n = 10), COPD with GERD (n =1 3 )
and disease control with GERD (n = 11). Statistically significance between asthma and COPD is indicated *p<0.05. Statistically significance between
COPD and disease control is indicated #p<0.05.
FSSG question number Asthma with GERD COPD with GERD Control
q1 1.0 (1.1) 0.8 (1.1) 1.4 (1.3)
q2 1.5 (0.8) 1.6 (1.0)# 1.0 (1.3)
q3 1.3 (1.4) 1.7 (1.0) 1.1 (1.2)
q4 0.8 (0.8) 1.1 (0.8) 1.6 (1.2)
q5 0.5 (0.5) 0.8 (0.2) 0.6 (1.0)
q6 1.3 (1.5) 0.7 (1.0) 1.2 (1.3)
q7 1.5 (1.4)* 0.5 (1.1) 1.5 (1.5)#
q8 0.5 (0.8) 1.5 (1.1) 1.5 (1.4)
q9 0.7 (0.8) 1.3 (0.8) 0.9 (1.2)
q10 0.7 (0.8) 0.5 (0.7) 1.2 (1.4)
q11 0.5 (0.5) 1.1 (0.9) 1.1 (1.4)
q12 0.2 (0.4) 0.2 (0.4) 1.2 (0.4)
Fig. 4. The mean scores for questions 2 and question 7 in COPD or
asthma patients with GERD having a history of disease exacerbation vs
patients without having a history of exacerbation. The scores of COPD
patients with GERD for question 2 (bloated stomach) (a). Scores are
compared between COPD patients with GERD having a history vs
without having a history of exacerbation. Scores of asthma patients
with GERD for question 7 (unusual sensation of the throat) (b). Scores
are compared between asthma patients with GERD having a history
vs without having a history of exacerbation. *Significant difference
between groups.doi: 10.3164/jcbn.11 75
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had more reflux symptoms than dysmotility symptoms, and FSSG
total score was inferior to QUEST for the dections of reflux
symptoms.(29) This might affect the negative result for the
detecting an increased risk of asthma exacerbation by FSSG. The
scores for questions 2 and 7 were higher in GERD patients with a
history of exacerbation of asthma or COPD than in GERD patients
without a history of exacerbation. These questions were useful
for detecting an increased risk of exacerbation. Previous reviews
have indicated an association of GERD with the risk of exacerba-
tion of asthma and COPD, but the potential effect of anti-reflux
therapy, (PPIs, etc.) on this relationship has not been deter-
mined.(7,37) Multi-drug therapy may be important in asthma and
COPD patients with GERD. In conclusion, dysmotility-related
symptoms were common in COPD patients, and useful questions
from the FSSG were an “unusual sensation in the throat” for
asthma patients or “bloated stomach” for COPD patients. GERD is
considered to be a risk factor for the exacerbation of COPD, but
the efficacy of PPI therapy is limited. The efficacy of PPIs may
differ between regurgitation-related symptoms and dysmotility-
related symptoms in asthma patients and COPD patients with
GERD.
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